|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/341 | (2006.01) |
| A61K 31/341 | (2013.01) | ||
| A61K 31/13 | (2006.01) | ||
| C07D 307/14 | (2013.01) | ||
| A61K 31/138 | (2006.01) | ||
| A61K 31/138 | (2013.01) | ||
| A61K 31/404 | (2006.01) | ||
| A61K 31/404 | (2013.01) | ||
| C07D 307/14 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 9/12 | (2006.01) |
| (11) | Number of the document | 3716968 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18884002.9 |
| Date of filing the European patent application | 2018-11-28 | |
| (97) | Date of publication of the European application | 2020-10-07 |
| (45) | Date of publication and mention of the grant of the patent | 2025-12-31 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/062853 |
| Date | 2018-11-28 |
| (87) | Number | WO 2019/108653 |
| Date | 2019-06-06 |
| (30) | Number | Date | Country code |
| 201762591248 P | 2017-11-28 | US |
| (72) |
MISSLING, Christopher, U. , US
|
| (73) |
Anavex Life Sciences Corp. ,
51 West 52nd Street 7th Floor, New York, NY 10019,
US
|
| (54) | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY |
| SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY |